Biogen Inc. (NASDAQ:BIIB) Sees Significant Increase in Short Interest

Biogen Inc. (NASDAQ:BIIB) was the target of a large growth in short interest in April. As of April 15th, there was short interest totaling 4,414,958 shares, a growth of 15.4% from the March 31st total of 3,826,441 shares. Currently, 3.0% of the shares of the stock are short sold. Based on an average daily volume of 1,439,919 shares, the days-to-cover ratio is presently 3.1 days.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on BIIB. Stifel Nicolaus upped their price target on Biogen from $202.00 to $214.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Tudor Pickering set a $201.00 target price on Biogen in a research report on Monday, February 9th. Wolfe Research set a $231.00 target price on Biogen in a report on Monday, February 9th. Mizuho raised their price target on Biogen from $207.00 to $236.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. Finally, Barclays initiated coverage on Biogen in a research note on Thursday, February 19th. They set an “equal weight” rating and a $185.00 price target for the company. Fourteen analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $213.12.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q1 beat — Biogen reported better‑than‑expected Q1 revenue and EPS (revenue $2.48B; non‑GAAP EPS $3.57), driven by growth-product sales and strong commercial execution, which is a key reason investors pushed the stock higher after results. Biogen Inc (BIIB) Q1 2026 Earnings Call Highlights
• Positive Sentiment: Growth-product tailwinds — Management highlighted in‑market LEQEMBI and SKYCLARYS sales and a Spinraza high‑dose approval; investors view these as sustainable revenue drivers that underpin the beat and longer‑term upside. Biogen shares rise after Q1 earnings beat, growth-product momentum, and pipeline/M&A updates
• Positive Sentiment: Analyst price‑target lifts — Multiple firms raised targets (RBC to $222, HC Wainwright to $237 and TD Cowen $215) and issued Buy/outperform notes, supporting upside prospects and helping offset guidance worries. RBC raises price target to $222 HC Wainwright raises PT to $237
• Neutral Sentiment: BMO keeps Hold — Some analysts remain cautious on near‑term growth and kept neutral/market‑perform ratings (BMO $196 PT), reflecting debate over how quickly new product momentum will offset costs. Biogen kept at Hold by BMO
• Neutral Sentiment: Mixed analyst views — Street reactions range from cautious to bullish; consensus price‑target dispersion is wide, so expect continued volatility as guidance clarity and M&A detail emerge. Analysts’ Opinions Are Mixed
• Negative Sentiment: Guidance trimmed on acquisition charges — Biogen narrowed FY‑2026 non‑GAAP EPS to $14.25–$15.25, citing acquisition‑related IPR&D and other M&A charges tied to business development (Apellis deal impacts), which trimmed some of the upside from the quarter and prompted concern over near‑term earnings. Biogen cuts annual profit forecast on acquisition-related charges (Reuters)
• Negative Sentiment: One‑time M&A costs weigh on outlook — Coverage notes the EPS trim reflects transaction costs rather than core operating weakness, but the cut still creates near‑term downside risk until the strategic rationale and integration benefits are clearer. Biogen beats Q1 but cuts 2026 EPS view (Zacks)

Insider Activity

In related news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the sale, the insider owned 8,043 shares in the company, valued at $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.18% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in BIIB. Empowered Funds LLC lifted its holdings in Biogen by 64.9% in the 1st quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock valued at $965,000 after purchasing an additional 2,777 shares in the last quarter. Focus Partners Wealth raised its position in shares of Biogen by 172.2% in the first quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock valued at $1,392,000 after buying an additional 6,436 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in shares of Biogen in the second quarter valued at approximately $216,000. Cerity Partners LLC lifted its stake in shares of Biogen by 15.3% during the second quarter. Cerity Partners LLC now owns 46,552 shares of the biotechnology company’s stock valued at $5,847,000 after buying an additional 6,184 shares during the period. Finally, NewEdge Advisors LLC lifted its stake in shares of Biogen by 13.4% during the second quarter. NewEdge Advisors LLC now owns 2,673 shares of the biotechnology company’s stock valued at $336,000 after buying an additional 316 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Trading Down 2.6%

Shares of Biogen stock opened at $189.28 on Friday. Biogen has a 1 year low of $115.25 and a 1 year high of $202.41. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.03. The business has a 50 day moving average price of $184.52 and a 200 day moving average price of $176.06. The company has a market capitalization of $27.78 billion, a P/E ratio of 20.31, a P/E/G ratio of 1.63 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The firm had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter in the prior year, the firm earned $3.02 EPS. Biogen’s quarterly revenue was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Sell-side analysts anticipate that Biogen will post 14.91 EPS for the current fiscal year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.